Cargando…
Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy
OBJECTIVES: No therapeutic interventions are currently available for autosomal dominant retinitis pigmentosa (adRP). An RPE65 Asp477Gly transition associates with late-onset adRP, reduced RPE65 enzymatic activity being one feature associated with this dominant variant. Our objective: to assess wheth...
Autores principales: | Kenna, Paul F, Humphries, Marian M, Kiang, Anna-Sophia, Brabet, Philippe, Guillou, Laurent, Ozaki, Ema, Campbell, Matthew, Farrar, G Jane, Koenekoop, Robert, Humphries, Pete |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228561/ https://www.ncbi.nlm.nih.gov/pubmed/32426524 http://dx.doi.org/10.1136/bmjophth-2020-000462 |
Ejemplares similares
-
Properties and Therapeutic Implications of an Enigmatic D477G RPE65 Variant Associated with Autosomal Dominant Retinitis Pigmentosa
por: Kiang, Anna-Sophia, et al.
Publicado: (2020) -
Phenotypic expansion of autosomal dominant retinitis pigmentosa associated with the D477G mutation in RPE65
por: Jauregui, Ruben, et al.
Publicado: (2020) -
Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa
por: Millington-Ward, Sophia, et al.
Publicado: (2011) -
RPE-Directed Gene Therapy Improves Mitochondrial Function in Murine Dry AMD Models
por: Millington-Ward, Sophia, et al.
Publicado: (2023) -
Toward an elucidation of the molecular genetics of inherited retinal degenerations
por: Farrar, G. Jane, et al.
Publicado: (2017)